Transcript Slide 1
„Cancerele rare, între bolile rare și cancerele comune” Sorin T. BARBU Clinica Chirurgie IV Universitatea de Medicina si Farmacie “Iuliu Hatieganu” Cluj-Napoca, Romania © S.T. Barbu 2015 Cacerul de Pancreas - intre cancerele Comune si bolile Rare Sorin T. BARBU Clinica Chirurgie IV Universitatea de Medicina si Farmacie “Iuliu Hatieganu” Cluj-Napoca, Romania © S.T. Barbu 2015 Cancerul Pancreatic Prognostic Infaust Supravietuire 1 an (toate Stadiile) < 18% Supravietuire 5 ani (toate Stadiile) < 4% © S.T. Barbu 2015 Cancerul Pancreatic 5 ani Supravietuire (globala) => •15-20% - pot fi rezecate •15-20% - 5 ani supravietuire © S.T. Barbu 2015 < 4% Cancerul Pancreatic 5 ani Supravietuire (globala) => < 4% •15-20% - pot fi rezecate •15-20% - 5 ani supravietuire => Neschimbat de > 30 ani! © S.T. Barbu 2015 De ce acest Prognostic? 2 cauze 1. Dg tardiv (< 20% pot fi rezecati curativ) - nu sunt simptome specifice - nu este posibil screening De ce acest Prognostic? 1. 2. Comportament Agresiv al tumorii (5 ani supravietuire < 20% ) • “Successful radical resection” – 2006 • Dies 2007 – “metastatic disease” De ce acest Prognostic? 1. Dg tardiv 2. Comportament Agresiv al tumorii 3. Atitudine Nihilistica fata de Tratamentul chirurgical al cancerului pancreatic a “primary physicians“ (+ gastroenterologi & oncologi) De ce acest Prognostic? “National failure to operate on early stage pancreatic cancer” Bilimoria et al. Ann Surg 2007. US – 1995 – 2004 (9559 pts T1,2NoMo) 71.4% of Stage I pancreatic cancer = No surgery! - 19.7% - due to Age, Commorbidities, Refusal - 51.7% - simply “not offered surgery” Cancer statistics, 2013; CA Cancer J Clin 2013; 63: Incidenta Cancer Pancreatic => Boala Rara EU def = < 5 din 10000 US def = < 200000 / an (2012 – 44000 cazuri noi; 13/100000) loc 4 - Deces prin cancer EU © S.T. Barbu 2015 Cancer statistics, 2013; CA Cancer J Clin 2013; 63: • COST Domain - Biomedicine and Molecular Biosciences (BMBS) © S.T. Barbu 2015 • EU_Pancreas at a glance The Action aims to unite groups across Europe interested in pancreas cancer research and provides an innovative and unique platform for collaborating and sharing information, ideas and experience 160 multidiciplinary members from: 21 EU countries 5 EU gov & non-gov institutions 3 Biotech companies (SME) 1 Pharma company Grant Period – 14 December 2012 to 13 December 2016 1st Grant Period – 31 May 2014 2nd Grant Period – 31 May 2015 www.eupancreas.com 13 © S.T. Barbu 2015 Eupancreas – National network © S.T. Barbu 2015 Eupancreas – National network © S.T. Barbu 2015 What is COST? © S.T. Barbu 2015 EU pancreas Obiective • realizarea unei retele de Centre Europene – cu BioBanci – stocare date clinice, epidemiologice, probe biologice => sursa pt Cercetare Europa • Evaluarea aplicabilitatii Tehnologiei Omics la identificarea de Markeri tumorali (moleculari, genetici, epigenetici) • Optimizarea metodologiei de interpretare si integrare a datelor • • • • Epidemiologice Statistice Bioinformatice genetice • Pregatirea tinerilor cercetatori (discipline diferite) din tari Europene • Diseminarea Informatiei la comunitatea stiintifica + publicul larg © S.T. Barbu 2015 EU pancreas © S.T. Barbu 2015 EU pancreas © S.T. Barbu 2015 EU pancreas © S.T. Barbu 2015 EU pancreas © S.T. Barbu 2015 EU pancreas © S.T. Barbu 2015 Pan-Europe Pancreatic Cancer Patient Association Pancreatic Cancer Action (UK). Ali Stunt, Chief Executive & Founder http://pancreaticcanceraction.org/ 24 EU pancreas Pancreas cancer Registry in Europe (prospective Registry) Purpose • to know the reality of the disease management (diagnosis, treatment, follow-up/survival) • to identify differences across centers and countries • to identify referral centers that could be accredited to manage pancreatic cancer patients. The disciplines mainly involved in this project are: - Surgery - Gastroenterologists - Radiologists - pathology. © S.T. Barbu 2015 Stakeholder meeting: 26 EU pancreas Conclusions EU Pancreas • is a unique platform to facilitate networking of European and international PC multidisciplinary research groups to integrate knowledge and experience in a multidisciplinary way • The ultimate aim is to foster PC research in Europe and to coordinate this effort with other international initiatives and consortia (ICGC, Panc4 and TCGA), • => to reduce pancreatic cancer mortality © S.T. Barbu 2015 Capacity building related to (WITHIN and BEYOND) COST networking Personalised Healthcare Fibre Laser BM1006 NGS 28 Take Home Message An integrated European platform for pancreatic cancer research November 2015 © S.T. Barbu 2015 November 2015 © S.T. Barbu 2015 November 2015 © S.T. Barbu 2014 November 2015 © S.T. Barbu 2015 November 2015 © S.T. Barbu 2014 November 2015 © S.T. Barbu 2015 November 2015 © S.T. Barbu 2015 November 2015 © S.T. Barbu 2015 November 2015 © S.T. Barbu 2015 Nov 2015 © S.T. Barbu 2015 Nov 2015 Informations [email protected] [email protected] [email protected] © S.T. Barbu 2015